Archive
2020, Volume 4
2019, Volume 3
2018, Volume 2
2017, Volume 1




Volume 3, Issue 2, December 2019, Page: 50-55
The Experience and Outcome of Renal Transplantation in Yemen
Nagib Wazea Abuasba, Nephrology Department, Faculty of Medicine, Sana’a University, Sana’a, Yemen
Ibrahim Al Nono, Nephrology Department, Faculty of Medicine, Sana’a University, Sana’a, Yemen
Tawfiq Al Badani, Nephrology Department, Faculty of Medicine, Sana’a University, Sana’a, Yemen
Abd Al Ilah Ghailan, Nephrology Department, Faculty of Medicine, Sana’a University, Sana’a, Yemen
Abdo Zekri, Nephrology Department, Faculty of Medicine, Sana’a University, Sana’a, Yemen
Received: Nov. 9, 2019;       Accepted: Nov. 28, 2019;       Published: Dec. 10, 2019
DOI: 10.11648/j.ijcu.20190302.15      View  163      Downloads  57
Abstract
Access to renal transplantation in the developing world remains limited It remains the treatment of choice for end-stage kidney disease. This procedure not only improves quality of life, but also markedly increases patients’ survival rates. Therefore, this study aimed to evaluate clinical outcomes of renal transplants in our center and to compare the outcomes between the patients who received induction therapy and those patients without such induction. It was a retrospective study conducted at Al Thawra General Hospital, Sana’a on 154 patients. Data were collected on all patients who underwent a renal transplant from 2004 to t 2015. Analyses were performed to assess baseline characteristics, graft and patient survival, as well as the outcomes of patients who given induction therapy. A total of 154 renal transplants were carried out at Al Thawra center. The mean age of patients was 32.42 ± 10.4 years (rang 14 – 66) and the male sex was predominant accounting for 72.7%. There were 93.5% of patients on dialysis and the dialysis time was ≥ 3 years in 72%. The major causes of end-stage kidney disease (ESKD) were chronic pyelonephritis (77.9%), hypertension (13%), glomerulonephritis (3.9%) and diabetes mellitus (2.4%). During the first year following renal transplants, 6 patients (3.9%) complicated by acute rejection episodes that did not reach statistical significance (P > 0.05). It is found that the mortality rate during the 1st, 5th, and 10th years was 1.9%, 9% and 14.9%respectively and the infectious conditions were the most frequent cause of death (13%) followed by cardiovascular events (3.9%) and others (2.5%). Although, the process of renal transplants in Yemen started slowly with the initial support and cooperation of the Egyptians’ transplant surgeons, the overall outcomes are satisfactory and comparable to the universal reports.
Keywords
Renal Transplantation, Graft Survival Rate, Yemen, Immunosuppressive
To cite this article
Nagib Wazea Abuasba, Ibrahim Al Nono, Tawfiq Al Badani, Abd Al Ilah Ghailan, Abdo Zekri, The Experience and Outcome of Renal Transplantation in Yemen, International Journal of Clinical Urology. Vol. 3, No. 2, 2019, pp. 50-55. doi: 10.11648/j.ijcu.20190302.15
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Chamsi-Pasha H, Albar M A kidney transplantation: ethical challenges in the arab world Saudi J Kidney Dis Transpl 2014; 25 (3): 489-495.
[2]
Schaapherder A, Wijermars L G M, de Vries D K, de Vries APJ, Bemelman F J, de Wetering J V et al Equivalent Long-term Transplantation Outcomes for Kidneys Donated After Brain Death and Cardiac Death: Conclusions From a Nationwide Evaluation EClinicalMedicine 2018; 4–5: 25–31.
[3]
Al Sayyari AA. The History of Renal Transplantation in the Arab World: A View From Saudi Arabia Am J Kidney Dis 2008; 51: 1033-1046.
[4]
Saadi M G, El-Khashab S O, Mahmoud R MA. Renal transplantation experience in Cairo University hospitals The Egyptian Journal of Internal Medicine, 2016; 28 (3): 116-122.
[5]
Kaballo M A, Canney M, Patrick O’Kelly P, Williams Y, O’Seaghdha C M, Conlon P J. A comparative analysis of survival of patients on dialysis and after kidney transplantation Clinical Kidney Journal, 2018, vol. 11, no. 3, 389–393.
[6]
Davidson B, Du Toit T, Jones ESW, Barday Z, Manning K, Mc Curdie F, et al. (2019)Outcomes and challenges of a kidney transplant programme at Groote Schuur Hospital, Cape Town: A South African perspective. PLoS ONE 14 (1): e0211189: https://doi.org/10.1371/journal.pone.0211189.
[7]
Organ Procurement and Transplant Network. ttps://optntransplanthrsagov/data/. Accessed January 2018.
[8]
ANZDATA. ANZDATA Annual Report for 2015. http://wwwanzdataorgau/v1/report_2016html. 2015.
[9]
Oliveira MI, Santos AM, Salgado Filho N. Survival analysis and associated factors to mortality of renal transplant recipients in a University Hospital in Maranhão. J Bras Nefrol 2012; 34: 216-25.
[10]
Rezapour S, Yarmohammadi A, Tavakkoli M. One-year survival rate of renal transplant: factors influencing the outcome Transplant Research and Risk Management 2017: 9 49–56.
[11]
Ritz E, Rychlيk I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis. 1999; 34 (5): 795–808.
[12]
Koch M, Thomas BeckerT, Lueck R, Neipp M, Klempnauer J, Nashan B. Basiliximab induction therapy in kidney transplantation: Benefi ts for long term allograft function after 10 years? Targets & therapy · February 2009.
[13]
YAO X, WENG G, WEI J and GAO W. Basiliximab induction in kidney transplantation with donation after cardiac death donors EXPERIMENTAL AND THERAPEUTIC MEDICINE 2016; 11: 2541-2546.
[14]
Lawen JG, Davies EA, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation. 2003; 75 (1): 37-43.
[15]
Hellemans R, J. - Bosmans L and Abramowicz D. Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies? American Journal of Transplantation 2017; 17: 22–27.
[16]
Wang JH, Skeans MA, Israni AK (2016) Current status of kidney transplant outcomes: dying to survive. Adv Chronic Kidney Dis 23 (5): 281–286.
[17]
Koyawala N, Silber JH, Rosenbaum PR et al.. Comparing outcomes between antibody induction therapies in kidney transplantation. J Am Soc Nephrol 2017; 28: 2188–2200.
[18]
Bicalho PR, Requião-Moura LR, Arruda ÉF, Chinen R, Mello L, Bertocchi APF, et al. LongTerm Outcomes among Kidney Transplant Recipients and after Graft Failure: A Single-Center Cohort Study in Brazil. BioMed Res Int. 2019; 1–10. DOI: 10.1155/2019/7105084.
[19]
Parrott, N. R.; Hammad, A. Q.; Watson, C. J., et al. (2005). Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients. Transplantation, Vol. 79, No. 3, (February 2005), pp. 344-8, ISSN 0041-1337.
[20]
Ribeiro MPDA, Sandes-Freitas TVD, Junior SMAR, Silva-Junior HT, Pestana JOM. Effect of induction therapy in kidney transplantation in sensitive patients: analysis of risks and benefits J Bras Nef rol 2016; 38 (1):82-89.
[21]
Afaneh C, Aull MJ, Schubl S, Leeser DB, Kapur S (2011) Induction Therapy: A Modern Review of Kidney Transplantation Agents. J Transplant Technol Res S4: 001. doi: 10.4172/2161-0991.S4-001.
[22]
Salvadori M, Tsalouchos A. Hepatitis C and renal transplantation in era of new antiviral agents World J Transplant 2018 August 9; 8 (4): 84-96.
[23]
Marinaki S, Kolovou K, Sakellariou S, Boletis JN, Delladetsima IK. Hepatitis B in renal transplant patients. World J Hepatol 2017; 9 (25): 1054-1063 Available from: URL: http://www.wjgnet.com/1948-5182/full/v9/i25/1054.htm DOI: http://dx.doi.org/10.4254/wjh.v9.i25.1054.
Browse journals by subject